Research Grants support investigators pursuing fundamental and applied MS research to advance roadmap goals of stopping disease activity, restoring function, and preventing new cases of MS.
The targeted RFA for early detection and diagnosis of MS in the 2026–2027 winter cycle has launched, replacing the previous planned-launch notice. Funding-opportunity email signup now uses a research mailing list instead of requests to msresearch@nmss.org.
Funder: National Multiple Sclerosis Society
Due Dates: Due Dates (Anticipated): Not yet announced
Funding Amounts: Research Grant budget and duration limits are set in each funding announcement
Summary: Supports investigator-initiated MS research addressing questions in the Pathways to MS Cures Roadmap.
Key Information: Principal investigators must hold an M.D., Ph.D. or equivalent; trainees and individuals in mentored positions are ineligible.
The National Multiple Sclerosis Society’s Research Grants support investigator-initiated fundamental and applied studies, including nonclinical and clinical research, patient management, care, and rehabilitation. Proposals must explain their relevance to at least one question in the Pathways to MS Cures Roadmap: stopping disease activity, restoring function by reversing damage and symptoms, or ending MS by preventing new cases. The Society values interdisciplinary collaboration, sharing data and resources, and research involving underserved and understudied ethnic and racial MS populations.
For the 2026–2027 winter cycle, the Society replaced the investigator-initiated opportunity with a targeted early-detection and diagnosis RFA administered through FIRST-MS. The Society expects to explore future investigator-initiated opportunities, with specific approaches still to be determined. The Research Grant rules below describe the investigator-initiated program; the targeted RFA has separate eligibility, scope, and funding.